Overview

Phase 1 to Study Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NA-931 in Obese Participants and Patients With Type 2 Diabetes Mellitus

Status:
COMPLETED
Trial end date:
2024-09-20
Target enrollment:
Participant gender:
Summary
A randomized, double-blind, placebo-controlled, dose escalation, first in human study designed to assess the safety and tolerability, pharmacokinetics, and pharmacodynamics of NA-931 when administered as single and multiple-ascending doses in overweight/obese participants and as multiple doses in patients with T2DM.
Phase:
PHASE1
Details
Lead Sponsor:
Biomed Industries, Inc.